Novel sterically hindered cannabinoid CB1 receptor ligands

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• Cannabinoid receptors (CB1 and CB2) are crucial targets for therapeutic intervention.
• Developing selective ligands for these receptors is essential for targeted drug development.
• Novel chemical scaffolds are needed to explore the structure-activity relationships of cannabinoid receptor ligands.

Purpose of the Study:

• To synthesize and characterize novel tetraphenyl derivatives as potential ligands for cannabinoid CB(1) and CB(2) receptors.
• To evaluate the binding affinity and selectivity of these compounds for CB(1) and CB(2) receptors.
• To investigate the functional activity of selective ligands as inverse agonists or antagonists.

Main Methods:

• Synthesis of 11 N-(3,3-diphenyl)propyl-2,2-diphenylacetamide derivatives and six triphenylacetamides.
• Radioligand binding assays to determine affinity (Ki) for CB(1) and CB(2) receptors.
• Functional assays measuring forskolin-induced cAMP formation in N18TG2 neuroblastoma cells to assess inverse agonism.

Main Results:

• All synthesized compounds showed affinity for both CB(1) and CB(2) receptors.
• Four compounds (4b, 9a, 9b, 11a) exhibited selectivity for CB(1) over CB(2) receptors.
• Compound 4b displayed potent CB(1) receptor affinity (Ki=58 nM) and 140-fold selectivity over CB(2) (Ki=7800 nM).
• Compound 4b acted as an inverse agonist, stimulating cAMP formation in N18TG2 cells.

Conclusions:

• Compound 4b represents a novel class of potent and selective CB(1) receptor inverse agonists.
• The easy synthesis and high affinity of compound 4b make it a valuable tool for designing new CB(1) receptor blockers.
• This discovery opens new possibilities for developing therapeutics targeting the CB(1) receptor for various medical conditions.